CBio [004] a & b Tumor Immunology Flashcards
Define Immunosurveillance
The three possible outcomes of Immunosurveillance?
elimination, equilibrium, and escape
What is RAG?
recombination-activating gene-2 (RAG2)
So, what is the role of the RAG gene in normal lymphocytes?
What is methylcholanthrene?
A chemical carcinogen
Other examples of co-inhibitory other than CTLA-4?
PD-1 and LAG-3
PD-1 stands for?
programmed cell death -1
FOXP3 mutations are x-linked
Action of TGF-Beta 1?
TGF-Beta 1: Inhibit proliferation and effector function of T cells Inhibit the activation of macrophages
Action of IL-10?
IL-10: It is an inhibitor of activated macrophages and dendritic cells Inhibit the expression of co-stimulators and class II MHC molecules on dendritic cells and macrophages
The T-cell ligand binding B7 on a professional antigen-presenting cell is:
A. CD28
B. CD2
C. LFA-1
D. ICAM-1
E. VCAM-1
A. CD28
The main costimulatory signal for activation of resting T-cells is provided by ligation of:
• A CD28
• B Surface Ig
• C LFA-1
• D VLA-4
• E IL-2
• A CD28
The normal immunological control of tumors is referred to as:
• A Immunological tolerance.
• B Immune surveillance.
• C Type III hypersensitivity.
• D Immunological silence.
• E Superantigen recognition
• B Immune surveillance
Cells bearing MHC class I plus peptide are targets for specific:
• A B-cells
• B Cytotoxic T-cells
• C Th1 cells
• D Th2 cells
• E Interdigitating dendritic cells
• B Cytotoxic T-cells
What is Ipilimumab?
anti-CTLA-4
What is Nivolumab?
PD-1 monoclonal Ab
Tumors whom Combination therapy of Ipilimumab (a CTLA-4) and Nivolumab (a PD-1) were proven effective?
advanced melanoma
Which of the following does not describe a documented mechanism of tumor-mediated immune evasion?
A. Down regulation of MHC class I
B. Secretion of TGF-Beta
C. Increase T reg
D. Antigenic variation
D. Antigenic variation
Tumor editing is one of the most difficult clinically relevant problems to overcome in the course of tumor therapy. Which one of the following accounts for the mechanism of tumor editing?
A. Survival of tumors with moderate expression of class II MHC molecules
B. Survival of tumors with low expression of class I MHC molecules
C. Survival of tumors with low expression of class II MHC molecules
D. Survival of tumors with high expression of class II MHC molecules
E. Survival of tumors with moderate expression of class I MHC molecules
B. Survival of tumors with low expression of class I MHC molecules